pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
406
stories
Aug 11, 26
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
fiercebiotech
Aug 11, 26
Abbott teams with Google Health on AI-powered health insights app
fiercebiotech
Aug 10, 26
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
biospace
Aug 10, 26
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
Aug 10, 26
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
Aug 6, 26
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
biopharma dive
Aug 6, 26
Tarsus bets $450M on Alkeus’ Stargardt drug
endpoints
Aug 6, 26
Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
fiercebiotech
Aug 6, 26
Opinion: STAT+: Stop asking if AI is good for medicine
stat
Aug 6, 26
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
Aug 5, 26
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
biospace
Aug 5, 26
The main therapy used for children with autism faces changes under Medicaid
stat
Aug 5, 26
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
Aug 4, 26
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
Aug 4, 26
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
Aug 3, 26
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
Aug 3, 26
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
Aug 3, 26
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
Jul 30, 26
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
Jul 30, 26
Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M
endpoints
Jul 30, 26
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
biospace
Jul 30, 26
Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases
stat
Jul 30, 26
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
stat
Jul 30, 26
Not-so-special delivery: When biopharmas fumble layoff news
biospace
Jul 29, 26
NSF testing new Ph.D. model giving trainees academic and industry experience
stat
Jul 29, 26
‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
fiercebiotech
Jul 29, 26
Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
fiercebiotech
Jul 28, 26
Visa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warn
stat
← prev
page 10 of 14
next →